Cerenome Third-Quarter Total Revenue of 0.7 Million Dollars Comes Entirely From Diagnostic Revenue: a Net Loss of 8.7 Million Dollars, or 1.14 Dollars per Share, and Cash of 4.9 Million Dollars
Cerenome, Inc. (Nasdaq: CNSY), a central nervous system oncology company, announced financial results for the third quarter ended September 30, 2026 in Houston on November 13, 2026, and provided an overview of recent business progress. The company rebranded from Plus Therapeutics during the quarter, and its stock began trading under the CNSY symbol on August 3, 2026.
Total revenue was 0.7 million dollars, consisting entirely of net diagnostic revenue. The company submitted billing claims for approximately 1.55 million dollars in gross billings at list prices and recognized 0.7 million dollars in net diagnostic revenue in the quarter after estimated payer adjustments and price concessions, in its first quarter of recognized CNSide diagnostic revenue, with commercial payments beginning in October.
Cost of revenue was 0.9 million dollars. Research and development expense was 2.1 million dollars, compared with 2.4 million dollars a year earlier, and selling, general and administrative expense was 5.2 million dollars, compared with 3.4 million dollars a year earlier. Operating loss was 7.5 million dollars, compared with 4.5 million dollars a year earlier. Net loss was 8.7 million dollars, or 1.14 dollars per share, compared with 4.4 million dollars, or 1.03 dollars per share, a year earlier.
Cash, cash equivalents and investments totaled 4.9 million dollars as of September 30, 2026, compared with 8.6 million dollars as of June 30, 2026. In September the company announced the closing of a senior secured financing facility of up to 20 million dollars, and it raised 3.8 million dollars under its Equity Distribution Agreement after the quarter ended.
On the business side, the company said its contracted coverage footprint now represents approximately 190 million covered lives and about 80 percent of United States private payers, with the Aetna agreement effective November 1 as the first national CNSide payer agreement to include both tumor cell enumeration and molecular profiling. Enrollment was completed in October in the Phase 2 ReSPECT-GBM study of REYOBIQ in recurrent glioblastoma, with topline data expected in mid-2027. The company will host a conference call on November 16, 2026 at 8:30 a.m. Eastern Time.
Source: Cerenome
Published by GSM · USA (original Chinese edition)
Photo: 图：脑部核磁共振影像（Cerenome相关资料图）。Raymond F Sekula Jr，CC BY 2.0，Wikimedia Commons。 / Photo: An MRI scan of the brain. Raymond F Sekula Jr, CC BY 2.0, via Wikimedia Commons.
British Insurer Aviva Reports Its Third Quarter 2026 Trading Update: General Insurance Premiums of 11.8 Billion Pounds, Up 19 Percent, a Combined Operating Ratio of 93.8 Percent and a Solvency II Cover Ratio of 179 Percent2026-11-14
Questerre Third-Quarter Production Averages 4,634 Barrels of Oil Equivalent per Day: Petroleum and Natural Gas Revenue of 50.8 Million Canadian Dollars and a Net Loss of 27.6 Million Canadian Dollars as the PX Energy Turnaround Finishes on Schedule, Released November 122026-11-14